Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOLA as Adjunct to BCAA in Hepatic Encephalopathy
NCT05539027Phase 4Completed
- Sponsor
- Ain Shams University
- Start
- Sep 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of l-ornithine l-aspartate in hepatic encephalopathy (HE) (2 arms), sponsored by Ain Shams University. Primary endpoint: Reversal of Hepatic encephalopathy or change of Hepatic encephalopathy by two grades at 5 days. Started Sep 2022; status: completed.
02
Drugs
l-ornithine l-aspartate
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT05539027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05539027.